Xeris Biopharma Holdings, Inc. — Form 8-K
Filed November 2, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 24/100
What the filing says
Xeris Biopharma appointed Menassie M. Taddese to its Board of Directors effective November 2, 2026, and assigned him to the Audit Committee. Taddese is a 30-year biopharmaceutical executive who most recently led Viatris's Emerging Markets business (~$3B revenue, 3,500 employees) and previously held senior finance and commercial roles at Pfizer, including CFO of Global Innovative Pharma North America (~$8B). No compensation, share grants, or financial terms were disclosed in the filing.
Why this rating
Board seat addition is routine governance; Taddese's credentials are strong but appointment creates no material financial impact. Typical advisory role for public biotech company.
See more from November 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.